Ritch 60 tablet: Each coated tablet contains Fexofenadine Hydrochloride USP 60 mg.
Ritch 120 tablet: Each coated tablet contains Fexofenadine Hydrochloride USP 120 mg.
Ritch 180 tablet: Each coated tablet contains Fexofenadine Hydrochloride USP 180 mg.
Ritch 30 ODT: Each orodispersible tablet contains Fexofenadine Hydrochloride USP 30 mg.
Ritch Suspension: Each 5 ml contains Fexofenadine Hydrochloride USP 30 mg.
Ritch is a preparation of Fexofenadine Hydrochloride which is an antihistamine with selective peripheral H1-receptor antagonist activity. Fexofenadine is rapidly absorbed after oral doses with peak plasma concentrations being reached in 2-3 hours. It is about 60% to 70% bound to plasma proteins. About 5% of the total doses is metabolized, mostly by the intestinal mucosa, with only 0.5% to 1.5% of the dose undergoing hepatic biotransformation by the cytochrome P450 system. Elimination half-life of 14 hours has been reported although this may be prolonged in patients with renal impairment. Excretion is mainly in the feces with only 10% being present in the urine. Fexofenadine does not appear to cross the blood-brain barrier.
Route of administration : Ritch tablet, ODT and suspension should be taken orally.
Ritch tablet Seasonal allergic rhinitis and chronic idiopathic urticaria: Adults and children 12 years and older: 60 mg twice daily or 120 mg once daily or 180 mg once daily with water. (Decreased renal function: 60 mg once daily starting dose).
Children 6 to 11 years: 30 mg twice daily (Decreased renal function: 30 mg once daily starting dose).
Ritch ODT (orodispersible tablet) Children aged 6 to 11 years: 30 mg ODT twice daily on empty stomach.
Ritch suspension:
Seasonal allergic rhinitis: Children 2 to 11 years: 30 mg (5 ml) twice daily.
Chronic idiopathic urticaria: Children 2 to 11 years: 30 mg (5 ml) twice daily; Children 6 months to <2 years: 15 mg (2.5 ml) twice daily.
Patients with renal impairment: Initial dose should be reduced to 60 mg once daily.
Aluminum and magnesium-containing antacids reduce fexofenadine bioavailability (separate administration by at least 2 hours); fruit juices (grapefruit, orange, apple) decrease absorption; erythromycin and ketoconazole increase fexofenadine levels.
Fexofenadine hydrochloride is contraindicated in patients with a known hypersensitivity to fexofenadine hydrochloride or any of its ingredients.
Common: Headache, drowsiness, nausea, dizziness.
Overdose
In case of an overdose, standard measures to remove any unabsorbed drug should be employed. Symptomatic and supportive treatment is recommended. There has been no reported case of an acute overdose of fexofenadine hydrochloride.
Category C. Inadequate well-controlled studies in pregnant women; use only if potential benefit justifies fetal risk. Lactation: Excretion in human milk unknown; caution should be exercised in nursing women.
Store below 25°C in a cool, dry place. Protect from light and moisture. Keep away from the reach of children.